INT117598

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2004
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 118
Total Number 125
Disease Relevance 41.25
Pain Relevance 48.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
Anatomy Link Frequency
superior 9
arm 7
joints 2
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
Infliximab 1444 99.80 Very High Very High Very High
methotrexate 3700 99.74 Very High Very High Very High
Etanercept 1373 99.72 Very High Very High Very High
abatacept 1813 99.66 Very High Very High Very High
Adalimumab 1589 99.40 Very High Very High Very High
Inflammation 870 98.76 Very High Very High Very High
rheumatoid arthritis 4457 98.56 Very High Very High Very High
Rheumatism 86 97.68 Very High Very High Very High
antagonist 547 97.44 Very High Very High Very High
Arthritis 1395 97.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disease 2254 99.28 Very High Very High Very High
Arthritis 343 98.76 Very High Very High Very High
Rheumatoid Arthritis 4615 98.56 Very High Very High Very High
Rheumatic Diseases 124 97.68 Very High Very High Very High
Seronegative Spondarthritis 1052 97.28 Very High Very High Very High
Infection 780 97.00 Very High Very High Very High
Hypersensitivity 40 96.68 Very High Very High Very High
Psoriasis 344 95.80 Very High Very High Very High
Disease Progression 73 95.72 Very High Very High Very High
Pulmonary Disease 32 94.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: After six months, the rates of ACR 20 responses were 50.4 percent in the abatacept group and 19.5 percent in the placebo group (P<0.001); the respective rates of ACR 50 and ACR 70 responses were also significantly higher in the abatacept group than in the placebo group (20.3 percent vs. 3.8 percent, P<0.001; and 10.2 percent vs. 1.5 percent, P=0.003).
Regulation (responses) of ACR
1) Confidence 0.26 Published 2005 Journal N. Engl. J. Med. Section Body Doc Link 16162882 Disease Relevance 0.06 Pain Relevance 0
In ARMADA, an ACR20 response was achieved in 25%, 52%, and 67% of adalimumab plus methotrexate recipients at weeks 1, 4, and 24, respectively.
Regulation (response) of ACR20 associated with adalimumab and methotrexate
2) Confidence 0.22 Published 2004 Journal BioDrugs Section Abstract Doc Link 15046527 Disease Relevance 0.46 Pain Relevance 0.76
At 3 months, a significantly greater percentage of patients in the etanercept 25 mg group achieved ACR20 and ACR70 responses than did controls (62% versus 23%, P < 0.001 [ACR20], and 41% versus 8%, P < 0.001 [ACR50]) [18].
Regulation (responses) of ACR20 associated with etanercept
3) Confidence 0.17 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.32 Pain Relevance 0.35
At 3 months, a significantly greater percentage of patients in the etanercept 25 mg group achieved ACR20 and ACR70 responses than did controls (62% versus 23%, P < 0.001 [ACR20], and 41% versus 8%, P < 0.001 [ACR50]) [18].
Regulation (responses) of ACR70 associated with etanercept
4) Confidence 0.17 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.32 Pain Relevance 0.35
Patients who received the infliximab 10 mg/kg regimens also showed superior improvement in ACR20, ACR50, and ACR70 response, compared with controls, for up to 102 weeks [41].
Regulation (response) of ACR50 in superior associated with infliximab
5) Confidence 0.17 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.20 Pain Relevance 0.39
Patients who received the infliximab 10 mg/kg regimens also showed superior improvement in ACR20, ACR50, and ACR70 response, compared with controls, for up to 102 weeks [41].
Regulation (response) of ACR20 in superior associated with infliximab
6) Confidence 0.17 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.20 Pain Relevance 0.39
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Regulation (response) of ACR50 associated with methotrexate
7) Confidence 0.15 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Secondary endpoints consisted of improvement in the DAS28, frequency of ACR50 and ACR70 responses, improvement of variables in the ACR core set, and overall improvement in the ACR criteria.
Regulation (responses) of ACR70
8) Confidence 0.15 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.37 Pain Relevance 0.08
Additionally, those patients receiving 4 mg/kg or 8 mg/kg of tocilizumab in combination with MTX also achieved an ACR50 and ACR70 response that was significantly increased in comparison with MTX alone.
Regulation (response) of ACR70 associated with methotrexate
9) Confidence 0.15 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.07 Pain Relevance 0.36
Secondary endpoints consisted of improvement in the DAS28, frequency of ACR50 and ACR70 responses, improvement of variables in the ACR core set, and overall improvement in the ACR criteria.
Regulation (responses) of ACR50
10) Confidence 0.15 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.37 Pain Relevance 0.08
At week 24, a consistent treatment effect for both rituximab groups versus placebo was observed for ACR, EULAR and DAS28-ESR responses in medically important subgroups, including baseline seropositivity (either RF or anti-cyclic citrullinated peptide (anti-CCP) antibody), duration of RA and baseline DAS28-ESR.
Regulation (responses) of ACR associated with rheumatoid arthritis
11) Confidence 0.15 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2938895 Disease Relevance 0.17 Pain Relevance 0.14
Patients who received the infliximab 10 mg/kg regimens also showed superior improvement in ACR20, ACR50, and ACR70 response, compared with controls, for up to 102 weeks [41].
Regulation (response) of ACR70 in superior associated with infliximab
12) Confidence 0.15 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.20 Pain Relevance 0.38
Efficacy measures included the proportion of patients who attained an ACR20 response at 24 weeks (primary end point) as well as the proportion of those who met ACR50 and ACR70 response criteria at the end of the study [34].
Regulation (response) of ACR20
13) Confidence 0.15 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.45 Pain Relevance 0.65
At 12 months, 72% of the patients in the group assigned to receive etanercept 25 mg had an ACR20 response, as compared with 65% of patients in the methotrexate group (P = 0.16) [23].
Regulation (response) of ACR20 associated with methotrexate and etanercept
14) Confidence 0.15 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.43 Pain Relevance 0.62
An ACR20 response at 24 weeks was attained by a significantly greater percentage of patients in the 20, 40, and 80 mg adalimumab plus methotrexate groups (47.8%, 67.2%, and 65.8%, respectively) than in the placebo plus methotrexate group (14.5%) (P < 0.001) [34].
Regulation (response) of ACR20 associated with adalimumab and methotrexate
15) Confidence 0.15 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC2833457 Disease Relevance 0.37 Pain Relevance 0.64
A statistically significantly higher percentage of patients in the 8 mg/kg group (40%) attained an ACR50 response compared with the placebo group (1.9%).
Regulation (response) of ACR50
16) Confidence 0.13 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.20 Pain Relevance 0.06
These changes correlated with a higher ACR response in both the tocilizumab and DMARD cohorts.
Regulation (response) of ACR
17) Confidence 0.13 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.13 Pain Relevance 0.10
In the combination groups, an ACR20 response was achieved by a statistically significantly greater number of patients compared with MTX plus placebo.
Regulation (response) of ACR20 associated with methotrexate
18) Confidence 0.13 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.08 Pain Relevance 0.36
The primary endpoint was achievement of an ACR20 response at week 12 using the last observation carried forward (LOCF) method.
Regulation (response) of ACR20
19) Confidence 0.13 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.44 Pain Relevance 0.09
The primary endpoint, an ACR20 response, was observed in a significantly higher proportion of patients receiving tocilizumab 4 mg/kg or 8 mg/kg (48% and 59%) versus methotrexate alone (26%).
Regulation (response) of ACR20 associated with methotrexate
20) Confidence 0.13 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.25 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox